Citations

Showing 10 of 108083 citations.

ITAM-containing adaptors regulate NKG2D-mediated cytotoxicity in human NK cells (138.15)
Neff, Jadee , Bida, Anya T., Schoon, Renee A., Dick, Christopher J., Leibson, Paul J., Billadeau, Daniel

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 184 | Issue: Supplement_1 | Pages: 138.15-138.15

10.4049/jimmunol.184.supp.138.15 Get It

Abstract NKG2D is expressed on cytotoxic lymphocytes and is an important immunosurveillance receptor that recognizes stress ligands such as MICA on tumor cells or virally infected cells. Unlike traditional immune activating receptors, NKG2D couples to the non-ITAM-containing transmembrane adaptor DAP10, which recruits PI3K and Grb2 to initiate target cell lysis. Current understanding predicts an ITAM-independent mechanism of NKG2D-mediated cytotoxicity. However, we show that in primary human NK cells, the ITAM-containing adaptors DAP12, FcϵR1γ, and CD3ζ selectively regulate the Grb2-Vav1 branch of NKG2D-mediated signal transduction and cytotoxicity. Furthermore, this ITAM-adaptor regulation of NKG2D is independent of ITAM activation. Thus our data reveal a more complex interplay between NKG2D and other activating receptors than was previously imagined, and we have uncovered a novel mechanism of ITAM-adaptor regulation of cell-mediated cytotoxicity. A more thorough understanding of immunoreceptor signaling networks will lead to more precise therapies when fighting diseases such as cancer, autoimmunity, and infection.
Mechanism of MDSC induced T cell tolerance in cancer (88.26)
Nagaraj, Srinivas, Cho, Hyun-II, Schrum, Adam G. , Celis, Esteban , Gabrilovich, Dmitry I.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 88.26-88.26

10.4049/jimmunol.182.supp.88.26 Get It

Abstract Tumor antigen-specific T-cell tolerance is a critical element of tumor escape. It is known that MDSC can induce antigen-specific CD8+ T cell tolerance in an experimental system with adoptive transfer of transgenic T cells. In this study we addressed the critical question whether a similar phenomenon can be observed in a "natural" non-transgenic experimental model. Balb/C mice were subcutaneously inoculated with two different tumor cell lines, a derivative A2L2 cell line, which expresses high levels of HER2/neu and the parental cell line 66.3. HER2/neu specific CD8+T cells were generated by immunization of mice with peptide. MDSC were able to tolerize antigen-specific T cells in vivo if they were collected from A2L2 but not from 66.3 tumor-bearing mice indicating the tumor-specific nature of T cell tolerance induced by MDSC. Next we investigated the type of signaling caused by MDSC in CD8+T cells that could lead to tolerance. MDSC dramatically reduced the ability of CD8+ T cells to respond to the specific peptide. However, study of various signaling molecules using different experimental systems and tests found that MDSC did not induce negative signaling in T cells. This conclusion was confirmed in adoptive transfer experiments with CD8+T cells expressing dual TCR: LCMV glycoprotein peptide gp33-41 and OVA-derived H-2Kb-restricted peptide ova257-264. We found that MDSC loaded with peptide specific for one TCR induced tolerance only against that specific epitope but CD8+ T cells retained the ability to respond to the peptide specific for the other TCR expressed on the same cell.
Haploinsufficiency of Flt3-ligand limits RAG1 locus activation (87.2)
Dolence, Joseph J., Gwin, Kimberly, Medina, Kay L.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 87.2-87.2

10.4049/jimmunol.182.supp.87.2 Get It

Abstract Evidence is accumulating that the molecular circuitry initiating lymphoid lineage specification correlates with expression of the receptor tyrosine kinase Flt3. Recombination activating gene-1 (RAG1) locus activation is a hallmark of lymphoid lineage specification. Previous studies established that expression of a RAG1-GFP/+ reporter begins in a subset of lineage negative (Lin-) cells that express high levels of c-kit and Sca-1 (LSK+). To investigate a regulatory connection between Flt3 signaling and RAG1 locus activation from this stage, RAG1-GFP/+ knockin mice expressing wildtype, heterozygote, and knockout Flt3-ligand (FL) alleles were generated. Mono-allelic expression of the FL gene reduced FL transcripts by half, providing an in vivo model to evaluate threshold requirements for FL in lymphocyte development. Percentages and numbers of LSK+ cells were similar in FL+/+ and FL+/- mice, but significantly decreased in FL-/- animals. Analysis of GFP expression within the LSK+ compartment revealed a FL dose dependent reduction in frequencies and numbers of GFP+ cells. The requirement for threshold levels of FL in regulation of GFP expression extended into the B220- c-kitlo IL-7R+ lymphoid progenitor and CD43+ B220+ Pro-B compartments, but not in later stage B cell precursors. These findings establish a critical requirement for FL in regulating one event in lymphoid specification, RAG1 locus activation. These studies were supported by startup funds to K.L.M. from Mayo Clinic.
The IFN-γ / IFN-γ Rα axis is involved in immunoediting of breast cancer that leads to the de novo generation of a novel breast cancer stem cell (BCSC)-like tumor variant and subsequent tumor recurrence (100.12)
Knutson, Keith L. , Kmieciak, Maciej , Knutson, Keith L. , Manjili, Masoud H.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 184 | Issue: Supplement_1 | Pages: 100.12-100.12

10.4049/jimmunol.184.supp.100.12 Get It

Abstract Tumor dormancy remains a major hurdle in the treatment of cancers. Recently, the association between cancer stem cells (CSC) and tumor dormancy has been speculated in variety of cancers. Despite conventional therapies of breast cancer, most of the US deaths are attributed to relapse which is likely due to a failure of current treatment regimens to eliminate breast cancer stem cells (BCSC). We reported IFN-γ-induced HER-2/neu antigen loss and tumor relapse. We performed in vitro and in vivo studies using neu positive mammary carcinoma (MMC) tumors and their dominant negative (dn) IFN-γ Rα MMC sub-line. We showed that IFN-γ producing CD8+ T cells induced the de novo generation of a distinct BCSC variant that differed from conventional BCSC. The novel phenotype: i) is not intrinsically quiescent, ii) is reversible by blocking IFN-γ Rα signaling in the tumor, iii) upregulates serine protease inhibitors (SPI-6/PI-9) and MUC-1 that could render the tumors refractory to granzyme/perforin- and antibody-induced apoptosis, respectively, and iv) downregulates HER-2/neu expression upon emerging under the immune pressure. While HER-2/neu+ conventional BCSC have been shown to be sensitive to HER-2/neu-targeted immunotherapy, these novel BCSC-like phenotypes are refractory to such immunotherapy because of HER-2/neu loss. Identification of such tumor immunoediting pathways and mechanisms is expected to improve immunotherapy of breast cancer, by pathway blocking strategies.
Amplifying TLR-MyD88 signals within tumor-specific T-cells enhances antitumor activity to low concentrations of subdominant tumor-antigens (101.35)
Dávila, Eduardo , Geng, Degui, Riker, Adam I., Markovic, Svetomir, Geng, Degui , Srivastava, Ratika , Markovic, Svetomir N.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 184 | Issue: Supplement_1 | Pages: 101.35-101.35

10.4049/jimmunol.184.supp.101.35 Get It

Abstract There is a dire need to understand the cellular signals that can potentiate T-cell responses to weakly immunogenic tumor antigens (TAg) and to tumors expressing suboptimal levels of these antigens. We examined the anti-tumor activity and survival of TLR2-MyD88-stimulated tumor-specific CD8 T-cells derived from melanoma patients and TAg-specific T-cell receptor transgenic pmel mice. TLR2 engagement on pmel CD8 T-cells, but not on TLR2-/-pmel or MyD88-/-pmel T-cells, reduced the activation threshold to a subdominant TAg, resulting in increased production of effector molecules and cytotoxicity. Wild-type or MyD88-/- mice treated with pmel T-cells and TLR2 ligand, but not TLR2-/-pmel or MyD88-/-pmel T-cells, showed significant tumor regression of an established melanoma tumor. Over-expressing TLR2 in pmel T-cells eradicated established tumors and four-times fewer cells were needed to generate anti-tumor responses. The enhanced anti-tumor activity was associated with improved survival and increased effector function of TLR2-MyD88-stimulated T-cells. Activating TLR-MyD88 signals in patient-derived T-cells reduced the activation threshold to several weakly immunogenic TAgs, resulting in increased cytokine production, expansion and cytotoxicity. These data highlight the physiological importance of activating TLR-MyD88 signals within tumor-reactive T-lymphocytes for enhancing their longevity and augmenting effector function against suboptimal levels of weakly-immunogenic antigens.
IQGAP1 mediates lymphocyte cytoskeletal polarization and peripheral effector functions (95.16)
Gorman, Jacquelyn A. , Gomez, Timothy S., Billadeau, Daniel D.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 95.16-95.16

10.4049/jimmunol.182.supp.95.16 Get It

Abstract IQGAP1 is a scaffolding protein that integrates the actin and microtubule cytoskeletons. Although IQGAP1 has been shown to participate in numerous cellular activities in fibroblasts and epithelial cells including E-cadherin-mediated cell-cell adhesion, cell polarity, motility, proliferation, and MAP kinase signaling, its function in thymocyte development or peripheral T cell effector functions has not yet been investigated. IQGAP1 localizes to the immune synapse in CD4+ and CD8+ T cells suggesting a possible role in T cell activation. Using wild type and IQGAP1-deficient mice, we demonstrate that neither thymocyte development nor peripheral T cells numbers are affected in the absence of IQGAP1. Surprisingly, IQGAP1-deficient CD4+ T cells make significantly more IL-2 compared to wild type cells. Despite this, IQGAP1-deficient T cells show diminished T cell proliferation and increased cell death following TCR and CD28 ligation, which is most likely due to increased activation-induced cell death. Interestingly, IQGAP1-deficient T cells spread abnormally in response to anti-CD3, fail to accumulate F-actin or polarize their microtubule-organizing center (MTOC) toward anti-CD3 coated beads. Consistent with the latter observation, CD8+ T cells do show defective cell-mediated killing. Furthermore, we find that IQGAP1-deficient T cells fail to polarize following integrin stimulation. Taken together, our data identify IQGAP1 as an important mediator of proper cytoskeletal polarization during T cell activation. This work was supported by NIAID grant AI065474 to D.D.B. and NIH -T32-AI07425 pre-doctoral Immunology Training Grant to J.A. Gorman.
Characterization of folate receptor positive macrophages and monocytes and folate receptor-mediated specific targeting in inflammation (92.10)
Hilgenbrink, Andrew R., Matteson, Eric L. , Lockwood, Michael B, Xia, Wei, Morgenstern, David , Cheng, Ji‐Xin , Low, Philip S.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 92.10-92.10

10.4049/jimmunol.182.supp.92.10 Get It

Abstract Folate receptor (FR) expressing macrophages have been shown to play an integral role in a number of inflammatory diseases. (1) In this report, we characterize these FR+ macrophages and further investigate whether monocytes, the precursors to these macrophages, also express FR. We demonstrate that FR expression is observed on a subset of highly activated peritoneal and synovial macrophages, but not on other infiltrating immune cells or resident macrophages. We further find that a subset of human peripheral blood monocytes also expresses FR, albeit at a lower level than activated macrophages. Surface antigen characterization of the FR+ monocytes suggests markers characteristic of an inflammatory phenotype (CD14hiCD16), while the resident monocytes (CD14loCD16+) express few or no FR. Preliminary clinical data also suggest that the numbers of peripheral FR+ monocytes can be reduced by a folate-targeted immunotherapy. These results suggest that activated macrophages and inflammatory monocytes express a FR that can be targeted with folate-linked drugs without promoting drug uptake by non-activated macrophages and resident monocytes. 1. Xia W, Hilgenbrink AR, et al. Blood. 2008 Oct 24. [Epub ahead of print] This work was supported in part by a grant from Endocyte, Inc.
NKAP, a novel modulator of Notch signaling, is required for T cell development (85.5)
Pajerowski, Anthony G., Nguyen, Chau , Shapiro, Michael J. , Shapiro, Virginia Smith , Aghajanian, Haig , Shapiro, Michael J

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 85.5-85.5

10.4049/jimmunol.182.supp.85.5 Get It

Abstract T cell development depends on the coordinated interplay between receptor signaling and transcriptional activation/repression. We performed a genetic complementation screen, and identified a novel transcriptional repressor, NKAP. NKAP associates with HDAC3 and is part of a DNA-binding complex, as shown by chromatin immunoprecipitation. NKAP also associates with CIR, a part of the Notch corepressor complex. The expression of NKAP during T cell development inversely correlates with the expression of Notch target genes, implying that NKAP may modulate Notch-mediated transcription. To examine the function of NKAP in T cell development, Lck-cre NKAP conditional knockout mice were generated. Interestingly, loss of NKAP blocks development of alpha/beta but not gamma/delta T cells. In addition, lck-cre NKAP cKO DP T cells express 8- to 20-fold higher levels of Hes1, Deltex1 and CD25, providing in vivo evidence that NKAP functions as a transcriptional repressor, acting at least in part, by repression of the Notch pathway.
Cellular and Humoral Immune Reactivity to Tumor-Associated Antigens in Chickens Infected with Rous Sarcoma Virus
Hall, Michael R., Qualtiere, Louis F., Hall, Michael R, Meyers, Paul A.

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 123 | Issue: 3 | Pages: 1097-1105

10.4049/jimmunol.123.3.1097 Get It

Abstract With a leukocyte blastogenesis assay and 3 M KCl extracts of chicken cells infected or infected and transformed by various avian tumor viruses (ATV), the time course of development of cellular reactivity in RSV tumor-bearing chickens to antigens expressed on these cell types was examined. Leukocyte reactivity to mitogens in RSV-injected birds was also investigated. Similarly, humoral responses to ATV-antigens and virus-induced antigens were assessed over time, by measuring the development of antiviral neutralizing antibody, as well as antibody to cell surface antigens on various cell types, by means of an isotopic antiglobulin test (IAT). There were no differences in phytohemmaglutinin responsiveness between the leukocytes of RSV-injected birds and control birds, but responses to pokeweed mitogen were sometimes elevated in RSV-injected animals. Cellular immunity to 3 M KCl extracts, principally to those extracts containing structural components of the virus envelope, developed between 3 and 5 weeks post-injection, during tumor growth and regression, and then declined, although the immune response could be restimulated by virus rechallenge. For the most part, responses to nonvirion tumor-specific surface antigen (TSSA) was weak except after RSV rechallenge. Humoral reactivity as measured by IAT also seemed to correlate well with the presence of virus envelope antigens (VEA) on infected indicator cells and appeared before antiviral neutralizing antibody. The data indicated that, at least during the primary response, major immune reactivity in RSV-injected birds appeared to be directed against VEA and that TSSA appeared to be most immunogenic when VEA was also present.
Regulatory CD4+CD25+FOXP3+ T-cells can be Converted into Cytotoxic Effectors (40.36)
Peikert, Tobias, Coughlin, Kathleen, Keulen, Virginia Van, Pease, Larry R. , Keulen, Virginia P. Van , Hansen, Michael

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 182 | Issue: Supplement_1 | Pages: 40.36-40.36

10.4049/jimmunol.182.supp.40.36 Get It

Abstract Background: Binding of the human IgM antibody B7-DC XAb to B7-DC on dendritic cells (DC) has profound immune modulatory effects. It enhances antigen presentation by DC, repolarizes T-helper (Th) 2 to Th1 cell responses, rapidly generates cytotoxic effectors and reprograms regulatory T-cells (Treg) into non-suppressive, cytokine producing autoimmune effectors. We hypothesized that co-culture of B7-DC XAb treated DC (DCXAb) with Treg results in the rapid generation of cytotoxic effectors. Methods: Bone marrow derived DC from wild type C57BL6 mice (WT-B6) were treated for 24 hours with either B7-DC XAb or a control human IgM antibody in the presence of melanoma cell lysate (B16). Subsequently, DCXAb were co-cultured with Treg (CD4+CD25+FOXP3+), Non-Treg (CD4+, CD25-), cytotoxic CD8+ T-cells isolated from WT-B6 mice and Treg from CD8 knockout mice (CD8 -/-). After re-isolation these T-cells were used in cytotoxic T-lymphocyte (CTL) assays targeting B16 and Thymic lymphoma (EL4) tumor cells. Results: Treg isolated from either WT-B6 mice or CD8 -/- mice co-cultured with B16 lysate treated DCXAb but not control antibody treated DC transformed into cytotoxic effectors targeting B16 but not EL4 tumor cells. Their level of cytotoxicity was comparable to that of CD8+ cells co-cultured with DCXAb. In contrast Non-Treg co-cultured with DCXAb did not kill in similar CTL assays. Conclusion: Co-culture of Treg with antigen treated DCXAb rapidly generates antigen specific cytotoxic effectors.